The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis

• Status: Terminated
• Trial end date: 2006-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Emotionally labile, depressed participants with multiple sclerosis treated with escitalopram will have a greater reduction in emotional lability scores and in their psychological distress scores than those who are randomized to receive placebo.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Weill Medical College of Cornell University
• Collaborator: Forest Laboratories
• Treatments: Antidepressive Agents; Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• Clinical diagnosis of multiple sclerosis

• Having mild to moderate depressive symptoms, with or without emotional lability

• Experiencing psychological distress

Exclusion Criteria:

• Meeting DSM-IV diagnostic criteria for Major Depressive Disorder or another Axis 1 diagnosis

• Cognitive impairment

• The presence of an unstable medical illness that might preclude completion of the study -